Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

Author:

Buitenkamp Trudy D.1,Izraeli Shai2,Zimmermann Martin3,Forestier Erik4,Heerema Nyla A.5,van den Heuvel-Eibrink Marry M.1,Pieters Rob16,Korbijn Carin M.6,Silverman Lewis B.7,Schmiegelow Kjeld8,Liang Der-Cheng9,Horibe Keizo10,Arico Maurizio11,Biondi Andrea12,Basso Giuseppe13,Rabin Karin R.14,Schrappe Martin15,Cario Gunnar15,Mann Georg16,Morak Maria16,Panzer-Grümayer Renate16,Mondelaers Veerle17,Lammens Tim17,Cavé Hélène18,Stark Batia19,Ganmore Ithamar2,Moorman Anthony V.20,Vora Ajay21,Hunger Stephen P.22,Pui Ching-Hon23,Mullighan Charles G.24,Manabe Atsushi25,Escherich Gabriele26,Kowalczyk Jerzy R.27,Whitlock James A.28,Zwaan C. Michel1

Affiliation:

1. Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands;

2. Department of Paediatric Haemato-Oncology, Edmond and Lily Safra Children’s Hospital, Sheba Medical Centre, Tel-Hashomer, Ramat Gan, and Tel Aviv University Medical School, Tel Aviv, Israel;

3. Statistical Office of Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;

4. Department of Medical Biosciences, University of Umeå, Umeå, Sweden;

5. Department of Pathology, The Ohio State University, Columbus, OH;

6. Dutch Childhood Oncology Group, The Hague, The Netherlands;

7. Dana-Farber Cancer Institute, Boston, MA;

8. Pediatric and Adolescent Medicine, the Juliane Marie Centre, the University Hospital Rigshospitalet, Copenhagen, Denmark;

9. Pediatric Hematology-Oncology Division, Mackay Memorial Hospital, Taipei, Taiwan;

10. Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Aichi, Japan;

11. Department Pediatric Hematology Oncology, Azienda Ospedaliero-Universitaria Meyer Children Hospital, Florence, Italy;

12. Departement of Pediatrics, Univerty of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy;

13. Pediatric Hemato-Oncology, Department of Pediatrics “Salus Pueri,” University of Padua, Padova, Italy;

14. Division of Pediatric Hematology/Oncology, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX;

15. Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany;

16. Children's Cancer Research Institute, St. Anna Children’s Hospital, University Medical School Vienna, Vienna, Austria;

17. Department of Pediatric Hemato-Oncology, Ghent University Hospital, Belgium;

18. Assistance Publique, Hôpitaux de Paris, Hôpital Robert Debré, Département de Génétique Université Paris-Denis Diderot, Paris, France;

19. Center of Pediatric Hematology/Oncology, Schneider Children's Medical Center of Israel, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;

20. Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;

21. Department of Haematology, Sheffield Children’s Hospital, Sheffield, United Kingdom;

22. Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital, Aurora, CO;

23. Department of Oncology and

24. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN;

25. Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan;

26. Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg–Eppendorf, Hamburg, Germany;

27. Department of Children’s Hematology and Oncology, Medical University, Lublin, Poland; and

28. Division of Haematology/Oncology, the Hospital for Sick Children, University of Toronto, Toronto, Canada

Abstract

Key Points Although the risk of ALL relapse is significantly higher in children with DS, good-prognosis subgroups have been identified. Patients with DS-ALL have higher treatment-related mortality throughout the treatment period independent of the therapeutic regimen.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3